29 August 2024
29 August 2024
The Centers for Medicare and Medicaid Services stated that savings of $3.7bn are predicted in the first year when negotiated drug prices apply.
The deal included an undisclosed upfront payment and NextRNA can get up to $547m if all the milestones are reached.
The FDA also plans to hold an advisory committee for the DCCR therapy for Prader-Willi syndrome, with a PDUFA date of 27 December 2024.
The companies will focus on two research programmes to analyse somatic tissue mutations.
The number of new oesophageal cancer cases annually is projected to increase by 80% before 2050. Find out about current and developing treatments set to improve patient outcomes.
Arcus turned to Hercules Capital’s financing for support and to advance its HIF-2α inhibitor casdatifan.
The approval is based on the data from the Phase III MERIT and SYNAPSE studies.
Biocon plans to commercialise Bmab 1200 in Europe, UK, Canada and Japan contingent on receipt of approvals.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
